Biofrontera Statistics
Total Valuation
Biofrontera has a market cap or net worth of $7.45 million. The enterprise value is $6.37 million.
Important Dates
The next estimated earnings date is Wednesday, May 14, 2025, after market close.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Biofrontera has 8.87 million shares outstanding. The number of shares has increased by 256.75% in one year.
| Current Share Class | 8.87M |
| Shares Outstanding | 8.87M |
| Shares Change (YoY) | +256.75% |
| Shares Change (QoQ) | +31.04% |
| Owned by Insiders (%) | 13.60% |
| Owned by Institutions (%) | 22.98% |
| Float | 6.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.12 |
| Forward PS | 0.16 |
| PB Ratio | 1.66 |
| P/TBV Ratio | 1.67 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.17 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.72, with a Debt / Equity ratio of 1.11.
| Current Ratio | 1.72 |
| Quick Ratio | 0.93 |
| Debt / Equity | 1.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.17 |
Financial Efficiency
Return on equity (ROE) is -384.98% and return on invested capital (ROIC) is -110.06%.
| Return on Equity (ROE) | -384.98% |
| Return on Assets (ROA) | -43.00% |
| Return on Invested Capital (ROIC) | -110.06% |
| Return on Capital Employed (ROCE) | -170.73% |
| Revenue Per Employee | $401,301 |
| Profits Per Employee | -$190,957 |
| Employee Count | 93 |
| Asset Turnover | 1.49 |
| Inventory Turnover | 2.12 |
Taxes
In the past 12 months, Biofrontera has paid $22,000 in taxes.
| Income Tax | 22,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -43.81% in the last 52 weeks. The beta is 0.37, so Biofrontera's price volatility has been lower than the market average.
| Beta (5Y) | 0.37 |
| 52-Week Price Change | -43.81% |
| 50-Day Moving Average | 0.91 |
| 200-Day Moving Average | 1.02 |
| Relative Strength Index (RSI) | 48.57 |
| Average Volume (20 Days) | 84,210 |
Short Selling Information
The latest short interest is 55,130, so 0.62% of the outstanding shares have been sold short.
| Short Interest | 55,130 |
| Short Previous Month | 97,753 |
| Short % of Shares Out | 0.62% |
| Short % of Float | 0.89% |
| Short Ratio (days to cover) | 0.60 |
Income Statement
In the last 12 months, Biofrontera had revenue of $37.32 million and -$17.76 million in losses. Loss per share was -$3.22.
| Revenue | 37.32M |
| Gross Profit | 18.71M |
| Operating Income | -17.21M |
| Pretax Income | -23.08M |
| Net Income | -17.76M |
| EBITDA | -16.79M |
| EBIT | -17.21M |
| Loss Per Share | -$3.22 |
Full Income StatementBalance Sheet
The company has $5.91 million in cash and $4.92 million in debt, giving a net cash position of $990,000 or $0.11 per share.
| Cash & Cash Equivalents | 5.91M |
| Total Debt | 4.92M |
| Net Cash | 990,000 |
| Net Cash Per Share | $0.11 |
| Equity (Book Value) | 4.43M |
| Book Value Per Share | 0.50 |
| Working Capital | 8.68M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$10.27 million and capital expenditures -$10,000, giving a free cash flow of -$10.28 million.
| Operating Cash Flow | -10.27M |
| Capital Expenditures | -10,000 |
| Free Cash Flow | -10.28M |
| FCF Per Share | -$1.16 |
Full Cash Flow StatementMargins
Gross margin is 50.14%, with operating and profit margins of -46.11% and -47.58%.
| Gross Margin | 50.14% |
| Operating Margin | -46.11% |
| Pretax Margin | -47.53% |
| Profit Margin | -47.58% |
| EBITDA Margin | -44.99% |
| EBIT Margin | -46.11% |
| FCF Margin | n/a |
Dividends & Yields
Biofrontera does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -256.75% |
| Shareholder Yield | -256.75% |
| Earnings Yield | -241.41% |
| FCF Yield | -139.74% |
Analyst Forecast
The average price target for Biofrontera is $7.00, which is 733.33% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.00 |
| Price Target Difference | 733.33% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 25.32% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on July 5, 2023. It was a reverse split with a ratio of 0.05:1.
| Last Split Date | Jul 5, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.05:1 |
Scores
Biofrontera has an Altman Z-Score of -7.65 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.65 |
| Piotroski F-Score | 4 |